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Background: Small studies have suggested that angiographic peri-stent contrast staining (PSS) at follow-up may predict subsequent late stent 
thrombosis.
Methods: HORIZONS-AMI was a dual-arm, factorial, randomized trial in STEMI pts. All 1382 follow-up angiograms in 1155 pts (median time 
to angiography 13.3 months) were analyzed for the presence of PSS (contrast staining outside the stent contour extending to ≥20% of the stent 
diameter). Serial intravascular ultrasound (IVUS) data (286 lesions in 268 pts) was evaluated to assess mechanisms of PSS.
Results: PSS was present in 24 (2.1%) pts at follow-up and was not more common with paclitaxel-eluting than bare metal stents (Table). All 7 PSS 
pts with follow-up IVUS had stent malapposition (vs 40.2% malapposition of the entire IVUS cohort); 3 were late acquired and 4 were persistent 
malapposition, and all but one showed positive vessel remodeling from baseline to follow-up (20.8±7.2 to 29.0±12.2mm2, p=0.13). During 3-year 
follow-up, subsequent stent thrombosis developed in 0/24 pts with PSS, compared to 11/1131 PSS-negative pts (0% vs. 1.0%, p=0.63, Table). The 
rates of revascularization and MACE were also not increased with PSS.
Conclusion: In the large-scale HORIZONS-AMI trial, PSS at angiographic follow-up was infrequent, was associated with late stent strut 
malapposition and positive remodeling, but was independent of stent type. In contrast to prior studies, identification of PSS was not a predictor of 
subsequent stent thrombosis. 
PSS present (n=24) PSS absent (n=1131) P=value
Paclitaxel-eluting stent use 19 (79.2%) 873 (75.6%) 0.68
Stent thrombosis
At 1 year 0 (0%) 5 (0.4%) 0.74
1 - 3 years 0 (0%) 11 (1.0%) 0.63
Total stent thrombosis 0 (0%) 16 (1.4%) 0.56
Target lesion revascularization at 3-years 4 (16.7%) 125 (11.1%) 0.41
Overall MACE 5 (20.5%) 325 (19.0%) 0.86
MACE = death, myocardial infarction, ischemic target vascular revascularization, or stroke
